Page 23 - Serum Institute Of India

India seeks to mend Bangladesh ties with coronavirus vaccine diplomacy

The new law fast-tracks Indian citizenship for non-Muslims from three neighboring nations including Bangladesh

Serum likely to submit final Covid-19 vaccine trial data in 10 days

If the data is found satisfactory, an approval for Covishield, Oxford-AstraZeneca's vaccine candidate, can come in by the first week of January

Codagenix, Serum to start UK trials of nasal Covid vaccine in January

The companies said 48 volunteers will be enrolled at three dose levels and expect to begin dosing the trial participants in the first week of January

Chennai Covishield volunteer to move court against Serum Institute

Serum Institute of India said the volunteer was "falsely laying the blame for his medical problems on the vaccine trial"

Serum Institute vax volunteer not ready to withdraw legal notice

A Chennai-based volunteer had developed severe neurological complications after first dose of vaccination of Covishield which is under development at Serum Institute

World is watching India for 'safe' Covid vaccine, but are we ready?

Review panel asks vaccine makers to submit more data to get authorisation

Experts ask Bharat Biotech for phase 3 data, Serum's UK approval status

Provide more safety data on Covid-19 vaccine: SEC to Serum, Bharat Biotech

The application submitted by the Pfizer was not discussed at the SEC meeting as the company has requested for more time for giving its presentation

Trust DCGI to ask for enough data before vaccine approval: Gagandeep Kang

Having achieved the first goal of seeing whether the vaccines work, we can be more ambitious and design studies to assess whether and how much they reduce transmission, says Kang

Expert panel set to review Pfizer-BioNTech, SII vaccine applications today

ICMR Director General Balram Bhargava said that in the case of temporary licensure or emergency use, the regulator had to be satisfied with the risk-benefit ratio.

Coronavirus LIVE: Covid-19 situation in Delhi stabilising, says NITI Aayog

Coronavirus live updates: At 18,55,341, Maharashtra has the highest number of coronavirus cases, followed by Karnataka 894,004, Andhra Pradesh 872,288, Tamil Nadu 791,552, and Kerala 639,664

Pfizer, Serum or Bharat Biotech - whose Covid vaccine will be India's 1st?

In this podcast, we will talk about the Covid Vaccine scenario, in which we will discuss trial results, efficacy among other things

Serum set for deal with Centre soon; to supply vaccine at Rs 250 a dose

There is still time before SII can start supplying to the low and medium income countries through Gavi

Decoded: What emergency use authorisation of Covid vaccine means for us

After the Indian arm of US pharmaceutical giant Pfizer, the Serum Institute of India has applied to the Drugs Controller General of India (DCGI) seeking emergency use authorisation

India weighing quick emergency review of Pfizer, AstraZeneca vaccines

Serum Institute is making AstraZeneca's Covid-19 vaccine in India and has applied for emergency use authorisation.

Serum seeks emergency use nod for Oxford's Covid-19 vaccine in India

According to the ICMR, the SII has already manufactured 40 million doses of the vaccine under the at-risk manufacturing and stockpiling license it obtained from the DCGI

DCGI reassures all protocols being followed in Serum's clinical trials

The ethics committee has seven members, including a chairperson who has to be from outside the institution where the trial is being conducted.

DCGI finds no link between Covid vaccine shot, 'adverse' reaction: Report

The DCGI arrived at the conclusion on Wednesday based on the recommendations of an independent expert committee which has also opined that compensation should not be paid to the volunteer

Adverse event in Serum's trial won't affect vaccine timelines: Health secy

Health ministry to come out with guidelines that will address the issues around vaccine safety to create awareness and dispel misinformation

AstraZeneca partner sticks with 2 full dose regimen in India Covid trials

The British drugmaker has said its COVID-19 vaccine could be up to 90% effective if administered as a half dose followed by a full dose